Claremont, CA (PRWEB) June 04, 2013
Because burns tend to heal slowly, become infected and remain inflamed, they can produce scars that are excessive, physically debilitating and functionally damaging. Each year in the US, more than 1 million burn injuries require medical attention. While over the last several decades advances in life saving technology have improved outcomes for burn patients, methods to prevent scar formation have not kept pace.
With support from the US Army Medical Research and Materiel Command, Synedgen is working to accelerate the burn healing process. This contract will expand Synedgen’s pipeline wound care portfolio and facilitate studies to further demonstrate the extent of Synedgen’s novel polysaccharide derivative to reduce inflammation and provide enhanced healing with the reduction of scarring. Funding will also support analysis of cellular mechanisms of scar formation and how the product mitigates this process.
“There is an urgent need to address wound healing and scar reduction in burn patients, and we are eager to continue our product development to improve outcomes for these patients,” stated Synedgen president Shenda Baker. “Synedgen’s product has been demonstrated in vivo and in vitro to reduce inflammation and infection in dermal wounds and to increase healing with significant reduction of scar tissue. The product is designed to control the inflammation, both due to tissue damage and to bacteria, and accelerate the regenerative environment to prevent the emergence of excessive scar formation.”
This work is supported by the US Army Medical Research and Materiel Command under Contract No. W81XWH-13-C-0053. The views, opinions and/or findings contained in this release are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Synedgen Inc. is an innovative pharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces.
Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at http://www.synedgen.com